Role of gamma-glutamyl transferase levels in prediction of high cardiovascular risk among patients with non-alcoholic fatty liver disease

KASAPOĞLU B., Turkay C., YALÇIN K. S., Carlioglu A., Koktener A.

INDIAN JOURNAL OF MEDICAL RESEARCH, vol.143, pp.30-36, 2016 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 143
  • Publication Date: 2016
  • Doi Number: 10.4103/0971-5916.178585
  • Journal Name: INDIAN JOURNAL OF MEDICAL RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.30-36
  • Keywords: BMI, cardiovascular disease risk score, Framingham, gamma glutamyl transferase, non-alcoholic fatty liver disease, non-obese, NATURAL-HISTORY, INSULIN-RESISTANCE, HEPATIC STEATOSIS, HEART-DISEASE, MORTALITY, INDIVIDUALS, HOMEOSTASIS, SEVERITY, FIBROSIS, OBESITY
  • Lokman Hekim University Affiliated: No

Abstract

Background & objectives: Non-alcoholic fatty liver disease (NAFLD) is an important cause of elevated liver functions. There is evidence showing an association between NAFLD and subclinical atherosclerosis independent of traditional risk factors. We undertook this retrospective study to determine the association of Framingham cardiovascular risk scoring system with liver function tests and inflammatory markers and to find the role of liver function tests in determination of CVD risk among non-obese and nondiabetic subjects with non-alcoholic fatty liver disease.